Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study
European Journal of Cancer · 2025-08 · 226 · 115625
DOI: 10.1016/j.ejca.2025.115625 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025-08. Verfasst von Salvatore Alfieri und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: salvatore.alfieri@…. Hauptthemen laut MEDLINE: DNA, Viral, Herpesvirus 4, Human, Epstein-Barr Virus Infections, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health.
Abstract (Originalsprache)
BACKGROUND: Plasma Epstein Barr Virus (EBV)-DNA is an established biomarker for endemic EBV-related nasopharyngeal carcinoma (NPC). Its relevance in non-endemic regions is less understood. This study longitudinally assessed plasma EBV-DNA (LEA study) throughout the curative management of non-endemic EBV-related NPC to evaluate its prognostic value. MATERIALS AND METHODS: Between 2012 and 2023, patients with non-endemic, non-metastatic, histologically confirmed EBER+ NPC treated at a tertiary center were retrospectively analyzed. Plasma EBV-DNA levels were measured at pre-treatment (T1), early (T2a, ≤6 weeks) and late (T2b, ≤14 weeks) post-treatment, during follow-up (T3), and after induction chemotherapy (T4), when applicable. EBV-DNA was analyzed for its association with recurrence-free survival (RFS). RESULTS: At a median follow-up of 60 months (range: 9-134), 167 patients were included. Median age was 50 years (range: 22-75), with 72 % male; 84 % had stage III-IV disease (TNM VIII Edition). Pre-treatment EBV-DNA was detected in 96 % of patients, with no predictive cut-off (median RFS: 43 vs. 62 months for detectable vs. undetectable EBV-DNA). Post-treatment undetectable EBV-DNA correlated with better RFS, also with no cut-off. Follow-up EBV-DNA anticipated recurrence in 71 % of cases by a median of 38 days (range: 11-365). Persistently negative follow-up EBV-DNA was observed in 91 % of non-recurrent patients; isolated positive spikes lacked prognostic significance. Post-induction chemotherapy EBV-DNA demonstrated a 92 % negative predictive value for recurrence. CONCLUSIONS: Plasma EBV-DNA is a valuable prognostic biomarker for non-endemic NPC. Pre- and post-treatment undetectable EBV-DNA holds a positive prognostic value. Post-induction EBV-DNA is the most informative timepoint. Longitudinal EBV-DNA monitoring is warranted in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: salvatore.alfieri@istitutotumori.mi.it.
- Department of Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: rebecca.romano@istitutotumori.mi.it.
- Department of Health Sciences, University of Milan, Milano, Italy.
- Department of Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy.
- Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
- Department of Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milano, Italy.
Förderung
- Ministry of Health
Zitieren
APA
Alfieri, S., Romanò, R., Marceglia, S., Sciortino, C., Ferrari Bravo, W., Zucchini, M., Piscitelli, M. L., Nuzzolese, I., Cavalieri, S., Bergamini, C., Colombo, E., Ottini, A., De Cecco, L., Lenoci, D., Iacovelli, N. A., Guzzo, M., Orlandi, E., Locati, L. D., Bossi, P., …, & Taverna, F. (2025). Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study. European Journal of Cancer, 226, 115625. https://doi.org/10.1016/j.ejca.2025.115625
Vancouver
Alfieri S, Romanò R, Marceglia S, Sciortino C, Ferrari Bravo W, Zucchini M, et al. Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study. European Journal of Cancer. 2025;226:115625. doi:10.1016/j.ejca.2025.115625
BibTeX
@article{Alfieri2025,
author = {Alfieri, Salvatore and Romanò, Rebecca and Marceglia, Sara and Sciortino, Carolina and Ferrari Bravo, Walter and Zucchini, Monica and Piscitelli, Maria Luigia and Nuzzolese, Imperia and Cavalieri, Stefano and Bergamini, Cristiana and Colombo, Elena and Ottini, Arianna and De Cecco, Loris and Lenoci, Deborah and Iacovelli, Nicola Alessandro and Guzzo, Marco and Orlandi, Ester and Locati, Laura Deborah and Bossi, Paolo and Licitra, Lisa and Taverna, Francesca},
title = {Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study},
journal = {European Journal of Cancer},
year = {2025},
volume = {226},
pages = {115625},
doi = {10.1016/j.ejca.2025.115625}
}
EUVIMED